List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3989487/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2022, 149, 76-77.	2.9	15
2	Progressive Depletion of B and T Lymphocytes in Patients with Ataxia Telangiectasia: Results of the Italian Primary Immunodeficiency Network. Journal of Clinical Immunology, 2022, 42, 783-797.	3.8	5
3	Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency. Journal of Clinical Immunology, 2022, 42, 253-265.	3.8	19
4	The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet). Journal of Clinical Immunology, 2022, 42, 935-946.	3.8	21
5	Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy. Biomedicines, 2022, 10, 1026.	3.2	11
6	T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies. Cells, 2022, 11, 1918.	4.1	11
7	Allergic manifestations of inborn errors of immunity and their impact on the diagnosis: A worldwide study. World Allergy Organization Journal, 2022, 15, 100657.	3.5	9
8	lgM, IgA and IgG response to conjugate polysaccharides in children with recurrent respiratory infections. Scandinavian Journal of Immunology, 2021, 93, e12955.	2.7	2
9	Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. Journal of Allergy and Clinical Immunology, 2021, 147, 520-531.	2.9	278
10	Differential Diagnostic in Cellular Immunodeficiencies. Rare Diseases of the Immune System, 2021, , 427-440.	0.1	0
11	COVID-19 – pathogenesis and immunological findings across the clinical manifestation spectrum. Current Opinion in Pulmonary Medicine, 2021, 27, 193-198.	2.6	8
12	Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral Centers. Frontiers in Immunology, 2021, 12, 627423.	4.8	25
13	International multicenter experience of transjugular intrahepatic portosystemic shunt implantation in patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2931-2935.e1.	3.8	4
14	Editorial: The Complexity of Primary Antibody Deficiencies. Frontiers in Immunology, 2021, 12, 635482.	4.8	1
15	lgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 655896.	3.9	55
16	Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2904-2906.e2.	3.8	56
17	Editorial: Trained Immunity-Based Vaccines. Frontiers in Immunology, 2021, 12, 716296.	4.8	4
18	Medical algorithm: Diagnosis and management of antibody immunodeficiencies. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3841-3844.	5.7	2

#	Article	IF	CITATIONS
19	Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up. Frontiers in Pediatrics, 2021, 9, 703853.	1.9	8
20	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. Biomedicines, 2021, 9, 1163.	3.2	18
21	COVID-19 in complex common variable immunodeficiency patients affected by lung diseases. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 535-544.	2.3	16
22	Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic. Expert Review of Clinical Immunology, 2021, 17, 163-168.	3.0	15
23	SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best. Journal of Clinical Immunology, 2021, 41, 1709-1722.	3.8	68
24	B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies. Cells, 2021, 10, 2915.	4.1	35
25	SARS-CoV-2 monoclonal antibody combination therapy in patients with COVID-19 and primary antibody deficiency. Journal of Infectious Diseases, 2021, , .	4.0	11
26	Poking COVID-19: Insights on Genomic Constraints among Immune-Related Genes between Qatari and Italian Populations. Genes, 2021, 12, 1842.	2.4	1
27	Granulomatous–lymphocytic interstitial lung disease: an international research prioritisation. ERJ Open Research, 2021, 7, 00467-2021.	2.6	6
28	The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency. Frontiers in Immunology, 2021, 12, 815404.	4.8	26
29	Cellular Immunology and COVID-19. Cells, 2021, 10, 3591.	4.1	0
30	Health-Related Quality of Life and Emotional Difficulties in Chronic Granulomatous Disease: Data on Adult and Pediatric Patients from Italian Network for Primary Immunodeficiency (IPINet). Journal of Clinical Immunology, 2020, 40, 289-298.	3.8	11
31	Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. Frontiers in Immunology, 2020, 11, 610300.	4.8	149
32	Managing Granulomatous–Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. Frontiers in Immunology, 2020, 11, 606333.	4.8	10
33	The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network;) Tj ETQq1 1 0.78	34314 rgBT	$^{-}$ /Overlock
34	IGA Antibody Induced by Immunization With Pneumococcal Polysaccharides Is a Prognostic Tool in Common Variable Immune Deficiencies. Frontiers in Immunology, 2020, 11, 1283.	4.8	15
35	The immune system of children: the key to understanding SARS-CoV-2 susceptibility?. The Lancet Child and Adolescent Health, 2020, 4, 414-416.	5.6	132
36	Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality. Journal of Allergy and Clinical Immunology, 2020, 146, 429-437.	2.9	59

#	Article	IF	CITATIONS
37	Transient hypogammaglobulinemia of infancy. , 2020, , 543-548.		0
38	Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1894-1899.e2.	3.8	64
39	Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype. Frontiers in Immunology, 2020, 11, 319.	4.8	8
40	The Usefulness of Scintigraphic Studies in the Assessment of Asymptomatic Bowel Disease in Patients with Primary Antibody Diseases. Journal of Clinical Medicine, 2020, 9, 949.	2.4	1
41	A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. Journal of Allergy and Clinical Immunology, 2020, 146, 211-213.e4.	2.9	275
42	Appropriate lung management in patients with primary antibody deficiencies. Expert Review of Respiratory Medicine, 2019, 13, 823-838.	2.5	14
43	Health-Related Quality of Life in Children and Adults with Primary Immunodeficiencies: A Systematic Review and Meta-Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1929-1957.e5.	3.8	28
44	Genetic stability of Campylobacter coli in patients with primary antibody deficiencies. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1707.	3.8	0
45	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. Leukemia Research, 2019, 87, 106233.	0.8	16
46	Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study. Journal of Clinical Immunology, 2019, 39, 159-170.	3.8	16
47	The high mortality of patients with common variable immunodeficiency and small bowel villous atrophy. Scandinavian Journal of Gastroenterology, 2019, 54, 164-168.	1.5	17
48	Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies. Journal of Allergy and Clinical Immunology, 2019, 144, 584-593.e7.	2.9	54
49	The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the ClinicalÂDiagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1763-1770.	3.8	381
50	Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. European Journal of Haematology, 2019, 102, 447-456.	2.2	60
51	Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group. Journal of Clinical Immunology, 2019, 39, 45-54.	3.8	32
52	Herd immunity and primary immune deficiencies. Vaccine, 2019, 37, 3942-3943.	3.8	3
53	Lack of Gut Secretory Immunoglobulin A in Memory B-Cell Dysfunction-Associated Disorders: A Possible Gut-Spleen Axis. Frontiers in Immunology, 2019, 10, 2937.	4.8	43
54	Differential Diagnosis in Hypogammaglobulinemia. Rare Diseases of the Immune System, 2019, , 235-252.	0.1	1

#	Article	IF	CITATIONS
55	Low Dose Azithromycin Prophylaxis in Primary Antibody Deficiencies. , 2019, , .		1
56	Intravenous immunoglobulin replacement treatment reduces in vivo elastase secretion in patients with common variable immune disorders. Blood Transfusion, 2019, 17, 103-111.	0.4	3
57	Fever and Sleepiness. , 2019, , 21-24.		Ο
58	Pulmonary diseases in primary immunodeficiency syndromes. , 2019, , 675-680.		0
59	The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative. Blood Transfusion, 2019, 17, 449-458.	0.4	5
60	Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. Journal of Allergy and Clinical Immunology, 2018, 142, 1285-1296.	2.9	185
61	Gastric Cancer Is the Leading Cause of Death in Italian Adult Patients With Common Variable Immunodeficiency. Frontiers in Immunology, 2018, 9, 2546.	4.8	58
62	The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. Orphanet Journal of Rare Diseases, 2018, 13, 201.	2.7	119
63	Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group. Frontiers in Immunology, 2018, 9, 2912.	4.8	48
64	UniVax Day 2018 ―Outreach to high school students to improve vaccination rates. European Journal of Immunology, 2018, 48, 1266-1268.	2.9	1
65	Risk factors for Haemophilus influenzae and pneumococcal respiratory tract colonization in CVID. Journal of Allergy and Clinical Immunology, 2018, 142, 1999-2002.e3.	2.9	17
66	Hyperâ€lgE in the allergy clinic––when is it primary immunodeficiency?. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2122-2136.	5.7	34
67	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18.	6.2	46
68	Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. International Immunopharmacology, 2017, 44, 38-42.	3.8	13
69	Health-Related Quality of Life and Patients' Empowerment in the Health Care of Primary Immune Deficiencies. Journal of Clinical Immunology, 2017, 37, 615-616.	3.8	9
70	Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells. Frontiers in Immunology, 2017, 8, 697.	4.8	18
71	The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement. PLoS ONE, 2017, 12, e0175961.	2.5	18
72	Clinical Associations of Biallelic and Monoallelic <i>TNFRSF13B</i> Variants in Italian Primary Antibody Deficiency Syndromes. Journal of Immunology Research, 2016, 2016, 1-14.	2.2	27

#	Article	IF	CITATIONS
73	Development and Initial Validation of a Questionnaire to Measure Health-Related Quality of Life of Adults with Common Variable Immune Deficiency: The CVID_QoL Questionnaire. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1169-1179.e4.	3.8	29
74	Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin therapy in complicated primary antibody deficiencies. Immunotherapy, 2016, 8, 995-1002.	2.0	8
75	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1019-1020.	3.8	0
76	Intravenous immunoglobulin replacement treatment does not alter polymorphonuclear leukocytes function and surface receptors expression in patients with common variable immunodeficiency. Cellular Immunology, 2016, 306-307, 25-34.	3.0	7
77	Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: AÂcohort study. Journal of Allergy and Clinical Immunology, 2016, 138, 210-218.e9.	2.9	215
78	International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 38-59.	3.8	669
79	Immunoglobulin-induced hemolysis, splenomegaly and inflammation in patients with antibody deficiencies. Expert Review of Clinical Immunology, 2016, 12, 725-731.	3.0	0
80	Otologic evaluation of patients with primary antibody deficiency. European Archives of Oto-Rhino-Laryngology, 2016, 273, 3537-3546.	1.6	5
81	Decreased IgM, IgA, and IgG response to pneumococcal vaccine in children with transient hypogammaglobulinemia of infancy. Journal of Allergy and Clinical Immunology, 2016, 137, 617-619.	2.9	14
82	Autoimmune lymphoproliferative syndrome in pregnancy: A case of favorable mother–fetal outcome in a wellâ€controlled disease. Journal of Obstetrics and Gynaecology Research, 2015, 41, 460-463.	1.3	2
83	Editorial: Immunoglobulin Therapy in the 21st Century – the Dark Side of the Moon. Frontiers in Immunology, 2015, 6, 436.	4.8	3
84	On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events. Frontiers in Immunology, 2015, 6, 11.	4.8	55
85	Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e98.	6.0	59
86	Intravenous immunoglobulin replacement induces an in vivo reduction of inflammatory monocytes and retains the monocyte ability to respond to bacterial stimulation in patients with common variable immunodeficiencies. International Immunopharmacology, 2015, 28, 596-603.	3.8	7
87	Lung Magnetic Resonance Imaging with Diffusion Weighted Imaging Provides Regional Structural as well as Functional Information Without Radiation Exposure in Primary Antibody Deficiencies. Journal of Clinical Immunology, 2015, 35, 491-500.	3.8	32
88	B cells from nuclear factor kB essential modulator deficient patients fail to differentiate to antibody secreting cells in response to TLR9 ligand. Clinical Immunology, 2015, 161, 131-135.	3.2	5
89	Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion, 2015, 55, 1067-1074.	1.6	22
90	Adequate Patient's Outcome Achieved with Short Immunoglobulin Replacement Intervals in Severe Antibody Deficiencies. Journal of Clinical Immunology, 2014, 34, 813-819.	3.8	18

#	Article	IF	CITATIONS
91	Manufacture of Immunoglobulin Products for Patients with Primary Antibody Deficiencies ââ,¬â€œ The Effect of Processing Conditions on Product Safety and Efficacy. Frontiers in Immunology, 2014, 5, 665.	4.8	21
92	Idiopathic Non Cirrhotic Portal Hypertension and Spleno-Portal Axis Abnormalities in Patients with Severe Primary Antibody Deficiencies. Journal of Immunology Research, 2014, 2014, 1-8.	2.2	30
93	Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe. Frontiers in Immunology, 2014, 5, 629.	4.8	76
94	Longitudinal Study on Health-Related Quality of Life in a Cohort of 96 Patients with Common Variable Immune Deficiencies. Frontiers in Immunology, 2014, 5, 605.	4.8	57
95	Intra-Erythrocyte Infusion of Dexamethasone Reduces Neurological Symptoms in Ataxia Teleangiectasia Patients: Results of a Phase 2 Trial. Orphanet Journal of Rare Diseases, 2014, 9, 5.	2.7	114
96	Intravenous immunoglobulin replacement therapy in common variable immunodeficiency induces B cell depletion through differentiation into apoptosis-prone CD21low B cells. Immunologic Research, 2014, 60, 330-338.	2.9	14
97	Dysregulated extracellular signal-regulated kinase signaling associated with impaired B-cell receptor endocytosis inÂpatients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 134, 401-410.e10.	2.9	17
98	Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects. Journal of Clinical Immunology, 2013, 33, 288-296.	3.8	26
99	Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency. Journal of Clinical Immunology, 2013, 33, 838-846.	3.8	39
100	Polyvalent immunoglobulins: challenges and perspectives. Blood Transfusion, 2013, 11 Suppl 4, s40-4.	0.4	6
101	Clinical use of polyvalent immunoglobulins. Blood Transfusion, 2013, 11 Suppl 4, s33-9.	0.4	4
102	Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. Blood, 2012, 120, 1953-1954.	1.4	69
103	Health Related Quality of Life in Common Variable Immunodeficiency. Yonsei Medical Journal, 2012, 53, 603.	2.2	52
104	High Prevalence of Intestinal Carriage of Campylobacter coli in Patients With Primary Antibody Deficiencies. Journal of Clinical Gastroenterology, 2011, 45, 474-475.	2.2	6
105	Lung MRI as a Possible Alternative to CT Scan for Patients With Primary Immune Deficiencies and Increased Radiosensitivity. Chest, 2011, 140, 1581-1589.	0.8	74
106	Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study. Journal of Clinical Immunology, 2011, 31, 315-322.	3.8	252
107	Efficacy and Safety of Subcutaneous Vivaglobin® Replacement Therapy in Previously Untreated Patients with Primary Immunodeficiency: A Prospective, Multicenter Study. Journal of Clinical Immunology, 2011, 31, 952-961.	3.8	48
108	Telomereâ€dependent replicative senescence of B and T cells from patients with type 1a common variable immunodeficiency. European Journal of Immunology, 2011, 41, 854-862.	2.9	22

#	Article	IF	CITATIONS
109	Circulating CD21 <sup>low</sup> B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13451-13456.	7.1	308
110	Regression of systemic lupus erythematosus after development of an acquired Tollâ€like receptor signaling defect and antibody deficiency. Arthritis and Rheumatism, 2009, 60, 2767-2771.	6.7	24
111	Prospective Study on CVID Patients with Adverse Reactions to Intravenous or Subcutaneous IgG Administration. Journal of Clinical Immunology, 2008, 28, 263-267.	3.8	33
112	The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood, 2008, 111, 77-85.	1.4	722
113	CpG Drives Human Transitional B Cells to Terminal Differentiation and Production of Natural Antibodies. Journal of Immunology, 2008, 180, 800-808.	0.8	209
114	Lymphoma in common variable immunodeficiency: interplay between immune dysregulation, infection and genetics. Current Opinion in Hematology, 2008, 15, 368-374.	2.5	70
115	A novel immunodeficiency characterized by the exclusive presence of transitional B cells unresponsive to CpG. Immunology, 2007, 121, 183-188.	4.4	23
116	Long-Term Follow-Up and Outcome of a Large Cohort of Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2007, 27, 308-316.	3.8	465
117	The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2005, 115, 412-417.	2.9	213
118	Human Immunoglobulin M Memory B Cells Controlling <i>Streptococcus pneumoniae</i> Infections Are Generated in the Spleen. Journal of Experimental Medicine, 2003, 197, 939-945.	8.5	578
119	European Surveillance of Immunoglobulin Safety—Results of Initial Survey of 1243 Patients with Primary Immunodeficiencies in 16 Countries. Clinical Immunology, 2002, 104, 231-236.	3.2	49
120	Clinical, Immunological, and Molecular Analysis in a Large Cohort of Patients with X-Linked Agammaglobulinemia: An Italian Multicenter Study. Clinical Immunology, 2002, 104, 221-230.	3.2	299
121	T-Cell Immune Activation in Children with Vertically Transmitted Hepatitis C Virus Infection. Viral Immunology, 2001, 14, 169-179.	1.3	6
122	Possible participation of polymorphonuclear cells stimulated by microbial immunomodulators in the dysregulated cytokine patterns of AIDS patients. Journal of Leukocyte Biology, 1997, 62, 60-66.	3.3	25
123	HCV infection in a patient with hyper-IgM syndrome. Journal of Clinical Immunology, 1996, 16, 321-325.	3.8	3
124	Agenesis of the corpus callosum, combined immunodeficiency, bilateral cataract, and hypopigmentation in two brothers. American Journal of Medical Genetics Part A, 1988, 29, 1-8.	2.4	96
125	Characterization of two patients with lymphomas of large granular lymphocytes. Cancer, 1984, 53, 445-452.	4.1	39